This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
2fmz
From Proteopedia
| Line 1: | Line 1: | ||
| - | [[Image:2fmz. | + | {{Seed}} |
| + | [[Image:2fmz.png|left|200px]] | ||
<!-- | <!-- | ||
| Line 9: | Line 10: | ||
{{STRUCTURE_2fmz| PDB=2fmz | SCENE= }} | {{STRUCTURE_2fmz| PDB=2fmz | SCENE= }} | ||
| - | + | ===Carbonic anhydrase activators. Activation of isoforms I, II, IV, VA, VII and XIV with L- and D- phenylalanine, structure with D-Phenylalanine.=== | |
| - | + | <!-- | |
| - | + | The line below this paragraph, {{ABSTRACT_PUBMED_16686544}}, adds the Publication Abstract to the page | |
| + | (as it appears on PubMed at http://www.pubmed.gov), where 16686544 is the PubMed ID number. | ||
| + | --> | ||
| + | {{ABSTRACT_PUBMED_16686544}} | ||
==About this Structure== | ==About this Structure== | ||
| Line 31: | Line 35: | ||
[[Category: Crystal structure]] | [[Category: Crystal structure]] | ||
[[Category: Lyase]] | [[Category: Lyase]] | ||
| - | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on | + | |
| + | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Tue Jul 29 04:32:25 2008'' | ||
Revision as of 01:32, 29 July 2008
Carbonic anhydrase activators. Activation of isoforms I, II, IV, VA, VII and XIV with L- and D- phenylalanine, structure with D-Phenylalanine.
Template:ABSTRACT PUBMED 16686544
About this Structure
2FMZ is a Single protein structure of sequence from Homo sapiens. Full crystallographic information is available from OCA.
Reference
Carbonic anhydrase activators. Activation of isoforms I, II, IV, VA, VII, and XIV with L- and D-phenylalanine and crystallographic analysis of their adducts with isozyme II: stereospecific recognition within the active site of an enzyme and its consequences for the drug design., Temperini C, Scozzafava A, Vullo D, Supuran CT, J Med Chem. 2006 May 18;49(10):3019-27. PMID:16686544
Page seeded by OCA on Tue Jul 29 04:32:25 2008
